Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC)

被引：0
|
作者：
Abbas, Anser Ali
Davelaar, John
Gai, Jessica
Brown, Zachariah
Levi, Abrahm
Linden, Sheila
Minasyan, Angela
Rodriguez, Christina
Pachter, Jonathan A.
Gong, Jun
Larson, Brent K.
Hendifar, Andrew Eugene
Lo, Simon
Gaddam, Srinivas
Kosari, Kambiz
Nissen, Nicholas
Pandol, Stephen Jacob
Burkhart, Richard
Zheng, Lei
Osipov, Arsen
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA USA
[2] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Verastem Inc, Needham, MA USA
[5] Samuel Oschin Canc Ctr, Cedars Sinai Med Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4024
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
    Jeong, J. H.
    Yoo, C.
    Kim, K-P.
    Chang, H-M.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 263 - 263
  • [22] A phase II study of peri-operative modified FOLFIRINOX in localized pancreatic ductal adenocarcinoma ( PDAC)
    Cecchini, Michael
    Salem, Ronald
    Robert, Marie
    Czerniak, Suzanne
    Rajaei, Moein
    Townsend, Jeffrey
    Blaha, Ondrej
    Zelterman, Daniel
    Thumar, Jaykumar
    Kortmansky, Jeremy
    Zaheer, Wajih
    Fischbach, Neal
    Persico, Justin
    Stein, Stacey
    Khan, Sajid
    Cha, Charles
    Billingsley, Kevin
    Kunstman, John
    Chowdhury, Sumedha
    Tseng, Robert
    Mauricio, Carlos
    Yugawa, Deanne
    Escobar-Hoyos, Luisa
    Johung, Kimberly
    Wiess, Christina
    Spickard, Erik
    Aushev, Vasily N.
    Laliotis, George
    Jurdi, Adham
    Liu, Minetta C.
    Lacy, Jill
    CANCER RESEARCH, 2024, 84 (02)
  • [23] Validation of response and survival biomarkers in a phase II trial of BPM 31510-IV in advanced refractory pancreatic ductal adenocarcinoma (PDAC)
    Subbiah, V.
    Nastke, M. D.
    Miller, G. M.
    Shah, P.
    Gesta, S.
    Rodrigues, L. O.
    Granger, E.
    Narain, N. R.
    Kiebish, M. A.
    Sarangarajan, R.
    Kundranda, M. N.
    ANNALS OF ONCOLOGY, 2020, 31 : S949 - S949
  • [24] Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma A Phase 2 Randomized Clinical Trial
    Sohal, Davendra P. S.
    Duong, Mai
    Ahmad, Syed A.
    Gandhi, Namita S.
    Beg, M. Shaalan
    Wang-Gillam, Andrea
    Wade, James L., III
    Chiorean, E. Gabriela
    Guthrie, Katherine A.
    Lowy, Andrew M.
    Philip, Philip A.
    Hochster, Howard S.
    JAMA ONCOLOGY, 2021, 7 (03) : 421 - 427
  • [25] Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma (PDAC) in the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
    Neoptolemos, J. P.
    Jones, R. P.
    Psarelli, E. E.
    Jackson, R.
    Ghaneh, P.
    Halloran, C. M.
    Palmer, D. H.
    Tjaden, C.
    Strobel, O.
    Hackert, T.
    Buechler, M. W.
    PANCREAS, 2019, 48 (10) : 1497 - 1498
  • [26] A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)
    Hidalgo, M.
    Epelbaum, R.
    Wolpin, B. M.
    Stemmer, S. M.
    Geva, R.
    Golan, T.
    Borazanci, E.
    Borad, M.
    Pedersen, K. S.
    Park, J. O.
    Ramirez, R.
    Peled, A.
    Lustig, T. M.
    Kashtan, O. Bohana
    Rosenfeld, O.
    Sorani, E.
    Schlienger, K.
    Haras, A. Vainstein
    Von Hoff, D. D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
    Melisi, D.
    Merz, V.
    Fazzini, F.
    Pietrobono, S.
    Zecchetto, C.
    Malleo, G.
    Landoni, L.
    Quinzii, A.
    Casalino, S.
    Pesoni, C.
    Gaule, M.
    Casetti, L.
    D'Onofrio, M.
    Gabbrielli, A.
    Bernardoni, L.
    Milleri, S.
    Butturini, G.
    Scarpa, A.
    Salvia, R.
    Bassi, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S897 - S897
  • [28] A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma
    Lee, Choong-kun
    Hwang, Ho Kyoung
    Jeung, Hei-Cheul
    Chon, Hongjae
    Park, Hyung Soon
    Kim, Min Hwan
    Park, Mi-Suk
    Kang, Chang Moo
    Choi, Hye Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [29] A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).
    Aung, Kyaw Lwin
    McWhirter, Elaine
    Welch, Stephen
    Wang, Lisa
    Lovell, Sophia
    Stayner, Lee-Anne
    Ali, Saara
    Malpage, Anne
    Makepeace, Barbara
    Ramachandran, Makilpriya
    Dhani, Neesha C.
    Hedley, David W.
    Knox, Jennifer J.
    Siu, Lillian L.
    Goodwin, Rachel Anne
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [30] Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (trial in progress)
    Bajor, David Lawrence
    Gutierrez, Martin
    Vaccaro, Gina M.
    Masood, Ashiq
    Brown-Glaberman, Ursa Abigail
    Grilley-Olson, Juneko E.
    Javle, Milind M.
    Kindler, Hedy L.
    Gbolahan, Olumide B.
    Shields, Anthony Frank
    Zalupski, Mark
    Schmitt, Michael W.
    Coveler, Andrew L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345